Pharma
Coempaken (Empagliflozin 12.5 mg / Metformin HCl 1000 mg)
Antidiabetic combination; Empagliflozin 12.5 mg and Metformin 1000 mg (28 tablets) for Type 2 Diabetes management.
Coempaken (Empagliflozin 12.5 mg / Metformin HCl 1000 mg)
Coempaken is a combination antidiabetic therapy containing Empagliflozin (an SGLT2 inhibitor) and Metformin Hydrochloride (a biguanide). This pack contains 28 tablets (4x7 Tablets). It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin works by reducing glucose reabsorption in the kidneys, while Metformin reduces glucose production in the liver and improves insulin sensitivity. This dual-action approach effectively lowers HbA1c levels.
You May Also Like
Combination DPP-4 inhibitor and Biguanide; 50 mg/500 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Combination DPP-4 inhibitor and Biguanide; 50 mg/1000 mg Sitagliptin/Metformin tablets for Type 2 Diabetes management.
Combination DPP-4 inhibitor and Biguanide; 50mg/500mg Vildagliptin/Metformin tablets for Type 2 Diabetes control.
Triple antidiabetic combo; Dapagliflozin 10 mg, Sitagliptin 100 mg, and Metformin ER 1000 mg (28 tablets) for Type 2 Diabetes.